Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1040 |
Name | chronic lymphocytic leukemia |
Definition | A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ATR over exp | Ceralasertib | chronic lymphocytic leukemia | predicted - sensitive | detail... |
TP53 mutant | Duvelisib | chronic lymphocytic leukemia | predicted - sensitive | detail... |
TP53 inact mut | AZD6482 | chronic lymphocytic leukemia | predicted - sensitive | detail... |
ATM loss | AZD6482 | chronic lymphocytic leukemia | sensitive | detail... |
TP53 inact mut | Ceralasertib + Ibrutinib | chronic lymphocytic leukemia | sensitive | detail... |
ATM loss | Ceralasertib + Ibrutinib | chronic lymphocytic leukemia | sensitive | detail... |
ATM inact mut | Olaparib | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Ibrutinib + Venetoclax | chronic lymphocytic leukemia | predicted - sensitive | detail... |
TP53 mutant | CG-806 | chronic lymphocytic leukemia | predicted - sensitive | detail... |
BRAF K601N | PLX8394 | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Ibrutinib | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Acalabrutinib | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Obinutuzumab + Venetoclax | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Venetoclax | chronic lymphocytic leukemia | sensitive | detail... |
TP53 mutant | Idelalisib + Rituximab | chronic lymphocytic leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00577278 | Phase II | Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | Active, not recruiting | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00829647 | Phase Ib/II | Dasatinib + Lenalidomide | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Withdrawn | 0 | |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Completed | USA | ITA | GBR | FRA | ESP | BEL | 11 |
NCT01087294 | Phase I | Anti-CD19 CAR-T cells | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01125176 | Phase II | Lenalidomide + Rituximab + Thalidomide | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL | Completed | USA | 0 |
NCT01173679 | Phase II | Dasatinib + Fludarabine + Rituximab | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Terminated | USA | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Completed | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | 1 |
NCT01296932 | Phase I | BI 836826 | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | Completed | FRA | DEU | BEL | 0 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01441882 | Phase II | Dasatinib | A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity | Completed | USA | 0 |
NCT01459211 | Phase II | Dexamethasone Lenalidomide | Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) | Completed | GBR | 0 |
NCT01532700 | Phase II | Afuresertib + Ofatumumab | An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) | Completed | CAN | 0 |
NCT01556776 | Phase III | Lenalidomide | A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy | Completed | DEU | 0 |
NCT01604031 | Phase Ib/II | Lenalidomide | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | Terminated | USA | 0 |
NCT01638533 | Phase I | Romidepsin | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | Active, not recruiting | USA | CAN | 0 |
NCT01644253 | Phase I | Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab | Phase 1b Safety and Efficacy Study of TRU-016 | Terminated | USA | 0 |
NCT01660451 | Phase II | Copanlisib | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 15 |
NCT01671904 | Phase I | Bendamustine + Obinutuzumab + Venetoclax Bendamustine + Rituximab + Venetoclax | A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia | Completed | USA | FRA | DEU | 0 |
NCT01685892 | Phase I | Obinutuzumab + Venetoclax | A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia | Completed | USA | GBR | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT01732913 | Phase III | Idelalisib Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | ITA | GBR | FRA | ESP | DEU | AUS | 12 |
NCT01732926 | Phase III | Idelalisib Bendamustine + Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 7 |
NCT01750567 | Phase II | Metformin | A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL | Active, not recruiting | USA | 0 |
NCT01799889 | Phase II | Entospletinib | A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 21 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01849276 | Phase I | Cytarabine + Metformin | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Terminated | USA | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT01885897 | Phase Ib/II | ALT-803 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT01889186 | Phase II | Venetoclax | A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion | Completed | USA | GBR | FRA | DEU | CAN | AUS | 1 |
NCT01905813 | Phase I | Dezapelisib + Itacitinib Dezapelisib | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT01980875 | Phase III | Idelalisib + Obinutuzumab Chlorambucil + Obinutuzumab | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | Terminated | USA | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT01980888 | Phase III | Bendamustine + Idelalisib + Rituximab | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 5 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02004522 | Phase III | Duvelisib Ofatumumab | A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 2 |
NCT02005289 | Phase II | Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | Active, not recruiting | USA | 0 |
NCT02005471 | Phase III | Venetoclax Bendamustine Rituximab | A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 10 |
NCT02015208 | Phase Ib/II | Ruxolitinib | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | Completed | CAN | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02044822 | Phase II | Idelalisib + Rituximab | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | Terminated | USA | ITA | GBR | FRA | ESP | BEL | AUT | AUS | 6 |
NCT02049515 | Phase III | Ofatumumab Duvelisib | A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 2 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT02100423 | Phase II | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Completed | USA | 0 | |
NCT02100852 | Phase I | Chlorambucil + Obinutuzumab + Umbralisib | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02131584 | Phase II | Ruxolitinib | Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
NCT02135133 | Phase II | Idelalisib + Ofatumumab | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | Active, not recruiting | USA | 0 |
NCT02141282 | Phase II | Venetoclax | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy | Completed | USA | 0 |
NCT02158091 | Phase Ib/II | Cyclophosphamide + Fludarabine + Rituximab Duvelisib | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | Active, not recruiting | USA | 0 |
NCT02160015 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02200848 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL | Terminated | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02222688 | Phase I | Cirmtuzumab | UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02242942 | Phase III | Chlorambucil + Obinutuzumab Obinutuzumab + Venetoclax | A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 12 |
NCT02249429 | Phase Ib/II | PQR309 | Open-Label, Non Randomized Phase 2 Study With Safety Run-In | Completed | USA | GBR | FRA | 3 |
NCT02251548 | Phase II | Cyclophosphamide + Fludarabine + Ibrutinib + Rituximab | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02268851 | Phase I | Ibrutinib + Umbralisib | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | Active, not recruiting | USA | 0 |
NCT02285244 | Phase II | Sotrastaurin | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | Withdrawn | 0 | |
NCT02292225 | Phase I | Duvelisib + Obinutuzumab | IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi | Terminated | USA | CAN | 0 |
NCT02296918 | Phase I | Acalabrutinib + Obinutuzumab | ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL | Active, not recruiting | USA | 0 |
NCT02301156 | Phase III | Ibrutinib + Ublituximab Ibrutinib | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 1 |
NCT02303392 | Phase I | Ibrutinib + Selinexor | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02315768 | Phase Ib/II | Ibrutinib + Obinutuzumab | Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | Active, not recruiting | USA | 0 |
NCT02319369 | Phase I | Milademetan | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies | Terminated | USA | 0 |
NCT02332980 | Phase II | Pembrolizumab | A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02340780 | Phase II | Buparlisib | Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | Completed | CAN | 0 |
NCT02361346 | Phase Ib/II | MT-3724 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) | Terminated | USA | ESP | CAN | 7 |
NCT02369016 | Phase III | Copanlisib | Phase III Copanlisib in Rituximab-refractory iNHL | Completed | ITA | 9 |
NCT02420912 | Phase II | Ibrutinib + Nivolumab | Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02427451 | Phase Ib/II | Ibrutinib + Obinutuzumab + Venetoclax | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | 1 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | FRA | ESP | BEL | 1 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Active, not recruiting | USA | GBR | FRA | 0 |
NCT02475681 | Phase III | Acalabrutinib Chlorambucil Obinutuzumab | Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 9 |
NCT02477696 | Phase III | Acalabrutinib Ibrutinib | Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 7 |
NCT02514083 | Phase II | Fludarabine + Ibrutinib | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | Active, not recruiting | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02535286 | Phase Ib/II | Pembrolizumab + Ublituximab + Umbralisib | Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL | Completed | USA | 0 |
NCT02537613 | Phase I | Ibrutinib + Obinutuzumab | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02538614 | Phase Ib/II | BI 836826 + Idelalisib | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT02557516 | Phase Ib/II | Ibrutinib + Monalizumab | Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT02580552 | Phase I | MRG-106 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Completed | USA | 0 |
NCT02611908 | Phase I | Ibrutinib + Obinutuzumab | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | Withdrawn | 0 | |
NCT02612311 | Phase III | Ublituximab Chlorambucil + Obinutuzumab Umbralisib | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | Completed | USA | ITA | GBR | ESP | 3 |
NCT02639910 | Phase II | Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix | Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) | Completed | USA | ITA | GBR | DEU | AUT | 1 |
NCT02649387 | Phase II | Ibrutinib | Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT) | Active, not recruiting | USA | 0 |
NCT02656303 | Phase II | Ublituximab + Umbralisib | An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 | Terminated | USA | ITA | GBR | 1 |
NCT02684617 | Phase I | Dinaciclib + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02717611 | Phase II | Acalabrutinib | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | Active, not recruiting | USA | GBR | FRA | ESP | BEL | 1 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02733042 | Phase Ib/II | Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) | Completed | USA | ITA | GBR | FRA | DEU | 2 |
NCT02742090 | Phase II | Umbralisib | Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | Completed | USA | 0 |
NCT02743546 | Phase I | Ibrutinib + JNJ-64052781 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma | Withdrawn | 0 | |
NCT02756611 | Phase III | Venetoclax | A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor (VENICE I) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02801578 | Phase I | Ibrutinib | A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02846623 | Phase II | Atezolizumab + Obinutuzumab + Venetoclax | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | Recruiting | USA | 0 |
NCT02860676 | Phase I | Cirmtuzumab | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | Completed | USA | 0 |
NCT02869633 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT02890758 | Phase I | ALT-803 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02912754 | Phase Ib/II | Ibrutinib Ibrutinib + Ruxolitinib | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | Unknown status | CAN | 0 |
NCT02914327 | Phase I | Ibrutinib + SNX-5422 | Safety and Activity of SNX-5422 Plus Ibrutinib in CLL | Withdrawn | USA | 0 |
NCT02948283 | Phase 0 | Metformin + Ritonavir | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02970318 | Phase III | Bendamustine + Idelalisib + Rituximab Acalabrutinib | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 15 |
NCT02973399 | Phase I | Ibrutinib + SNX-5422 | Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | Terminated | USA | 0 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03037645 | Phase Ib/II | Vecabrutinib | Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers | Terminated | USA | 0 |
NCT03041636 | Phase II | Ruxolitinib | Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT03045328 | Phase Ib/II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | Completed | USA | 0 |
NCT03056339 | Phase Ib/II | Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | Completed | USA | 0 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 2 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03128879 | Phase II | Acalabrutinib + Venetoclax Ibrutinib + Venetoclax | Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | Recruiting | USA | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03153202 | Phase Ib/II | Ibrutinib + Pembrolizumab | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | Recruiting | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03207256 | Phase II | Ublituximab + Umbralisib Umbralisib | Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | Terminated | USA | 0 |
NCT03207555 | Phase II | Ibrutinib | Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
NCT03219450 | Phase I | NeoVax Cyclophosphamide + NeoVax | A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naive, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia. | Recruiting | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | GBR | DEU | 1 |
NCT03265717 | Phase II | INVAC-1 | DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT03283137 | Phase I | Pembrolizumab + Umbralisib | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | Active, not recruiting | USA | 0 |
NCT03331198 | Phase Ib/II | Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Active, not recruiting | USA | 0 |
NCT03336333 | Phase III | Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | BEL | AUT | AUS | 7 |
NCT03370185 | Phase II | Duvelisib | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Withdrawn | USA | 0 |
NCT03379051 | Phase Ib/II | Ublituximab + Umbralisib + Venetoclax | Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL | Terminated | USA | 0 |
NCT03400176 | Phase I | Ibrutinib + VAY736 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Terminated | USA | 0 |
NCT03406156 | Phase III | Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | Completed | USA | 0 |
NCT03422393 | Phase I | Ibrutinib + Venetoclax Venetoclax | Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib | Active, not recruiting | USA | 0 |
NCT03447808 | Phase I | Daratumumab + Ibrutinib | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03454165 | Phase I | BNC105P + Ibrutinib | A Study of BNC105P Combined With Ibrutinib | Completed | USA | 0 |
NCT03462719 | Phase III | Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | BEL | 8 |
NCT03467867 | Phase II | Hyaluronidase + Rituximab + Venetoclax Rituximab + Venetoclax | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Active, not recruiting | USA | 0 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03513562 | Phase II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | Active, not recruiting | USA | 0 |
NCT03514017 | Phase II | Ibrutinib + Pembrolizumab | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | Terminated | USA | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Recruiting | USA | 0 |
NCT03534323 | Phase Ib/II | Duvelisib + Venetoclax | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL | Recruiting | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03579888 | Phase I | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-Specific T Cells Post AlloSCT | Terminated | USA | 0 |
NCT03580928 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) | Active, not recruiting | USA | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03609593 | Phase II | Rituximab Bendamustine + Rituximab Venetoclax | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03624036 | Phase Ib/II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) | Terminated | USA | ITA | 0 |
NCT03639324 | Phase I | Idelalisib + Rituximab + Venetoclax | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL (RIVe-CLL) | Withdrawn | 0 | |
NCT03671590 | Phase I | Edralbrutinib Edralbrutinib + Ublituximab + Umbralisib | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | Active, not recruiting | AUS | 1 |
NCT03701282 | Phase III | Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 1 |
NCT03734198 | Phase II | Daratumumab + Ibrutinib | Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) | Active, not recruiting | FRA | 0 |
NCT03737981 | Phase III | Ibrutinib + Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab | Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03739554 | Phase I | CYC065 + Venetoclax | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL | Active, not recruiting | USA | 0 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | ITA | GBR | FRA | AUS | 5 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Active, not recruiting | GBR | FRA | ESP | AUS | 0 |
NCT03759184 | Phase I | Obinutuzumab + rhIL-15 | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | Terminated | USA | 0 |
NCT03766763 | Phase II | Venetoclax | Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A | Recruiting | FRA | 0 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | ITA | FRA | ESP | 2 |
NCT03788291 | Phase II | Acalabrutinib + Rituximab | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT03801525 | Phase II | Ublituximab + Umbralisib + Venetoclax | Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL (ULTRA-V) | Terminated | USA | 0 |
NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03824483 | Phase II | Obinutuzumab + Venetoclax + Zanubrutinib | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | Recruiting | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03836261 | Phase III | Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 20 |
NCT03893682 | Phase I | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT03900598 | Phase I | JNJ-67856633 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 5 |
NCT03943342 | Phase II | Ibrutinib Ibrutinib + Venetoclax | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | Withdrawn | 0 | |
NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT03986034 | Phase II | Venetoclax | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04008706 | Phase III | Acalabrutinib | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 9 |
NCT04010968 | Phase II | Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab | Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC) | Active, not recruiting | FRA | 0 |
NCT04016805 | Phase II | Ublituximab + Umbralisib + Venetoclax Ibrutinib + Ublituximab + Umbralisib | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax | Terminated | USA | 0 |
NCT04029038 | Phase Ib/II | CD19/CD22 CAR T cells | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | Withdrawn | USA | 0 |
NCT04043845 | Phase I | Ibrutinib + LY3214996 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Withdrawn | 0 | |
NCT04116437 | Phase II | Zanubrutinib | A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib | Recruiting | USA | 0 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Recruiting | USA | 0 |
NCT04149821 | Phase II | Ublituximab + Umbralisib | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Terminated | USA | 0 |
NCT04155840 | Phase II | Bendamustine + Copanlisib + Rituximab | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04163718 | Phase II | Umbralisib | TGR-1202 (Umbralisib) in Treatment Naive Patients With Chronic Lymphocytic Leukemia (CLL) | Terminated | USA | 0 |
NCT04169737 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04178798 | Phase III | Acalabrutinib | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | ESP | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04209621 | Phase II | Duvelisib + Ibrutinib | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04210219 | Phase I | JNJ-64264681 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | GBR | 5 |
NCT04230304 | Phase II | Daratumumab + Ibrutinib | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | Active, not recruiting | USA | 0 |
NCT04240704 | Phase I | JBH492 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | Active, not recruiting | ESP | DEU | 5 |
NCT04245722 | Phase I | Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide + Fludarabine + FT596 Cyclophosphamide + Fludarabine + FT596 + Rituximab | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Terminated | USA | 0 |
NCT04269902 | Phase III | Obinutuzumab + Venetoclax | Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study | Recruiting | USA | CAN | 0 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04285567 | Phase III | Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 0 |
NCT04305444 | Phase II | DTRMWXHS-12 + Everolimus + Pomalidomide | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | Recruiting | USA | 0 |
NCT04358458 | Phase Ib/II | GEN3009 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Terminated | USA | FRA | ESP | BEL | 2 |
NCT04419389 | Phase Ib/II | Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | Terminated | USA | 0 |
NCT04419519 | Phase II | Venetoclax | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | Recruiting | USA | 0 |
NCT04447768 | Phase II | Obinutuzumab + Venetoclax | The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
NCT04502394 | Phase Ib/II | Acalabrutinib + KRT-232 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Recruiting | USA | ITA | GBR | FRA | BEL | AUS | 5 |
NCT04509700 | Phase II | Parsaclisib Itacitinib + Parsaclisib | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Recruiting | USA | ITA | GBR | FRA | ESP | BEL | AUT | 10 |
NCT04512105 | Phase I | Azacitidine + Pitavastatin + Venetoclax Decitabine + Pitavastatin + Venetoclax Pitavastatin + Venetoclax | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04515238 | Phase II | Bendamustine + Obinutuzumab + Venetoclax + Zanubrutinib | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG) | Active, not recruiting | DEU | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | GBR | FRA | ESP | AUS | 3 |
NCT04560322 | Phase II | Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab + Venetoclax | Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL | Recruiting | USA | 0 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Recruiting | USA | 0 |
NCT04608318 | Phase III | Ibrutinib Ibrutinib + Venetoclax Obinutuzumab + Venetoclax | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17) | Active, not recruiting | ITA | ESP | DEU | BEL | AUT | 8 |
NCT04623541 | Phase Ib/II | Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE CLL-1) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |
NCT04624633 | Phase II | Acalabrutinib + Ublituximab + Umbralisib | AU2 In Relapsed and Untreated CLL | Active, not recruiting | USA | 0 |
NCT04657094 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT04657224 | Phase I | JNJ-64264681 + JNJ-67856633 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | FRA | ESP | BEL | AUS | 7 |
NCT04660045 | Phase II | Acalabrutinib | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Withdrawn | USA | 0 |
NCT04679012 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | Recruiting | USA | 0 |
NCT04684108 | Phase I | SG301 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | Withdrawn | AUS | 0 |
NCT04685915 | Phase II | Copanlisib + Ibrutinib | Copanlisib Plus Ibrutinib in R/R CLL | Withdrawn | 0 | |
NCT04722172 | Phase II | Acalabrutinib + Obinutuzumab | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | Active, not recruiting | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04781855 | Phase I | Ibrutinib + Ipilimumab Ibrutinib + Ipilimumab + Nivolumab | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | Active, not recruiting | USA | 0 |
NCT04806035 | Phase I | TG-1801 + Ublituximab TG-1801 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Active, not recruiting | USA | 0 |
NCT04876092 | Phase I | Ibrutinib + JNJ-67856633 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in B-cell NHL and CLL | Active, not recruiting | FRA | 3 |
NCT04883749 | Phase II | Acalabrutinib | Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail) | Active, not recruiting | DEU | AUT | 0 |
NCT04895436 | Phase II | Obinutuzumab + Venetoclax | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | ITA | ESP | DEU | AUT | AUS | 4 |
NCT04978779 | Phase I | VIP152 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | Terminated | USA | 1 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Recruiting | USA | AUS | 1 |
NCT05005299 | Phase I | Cyclophosphamide + Fludarabine + Venetoclax | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) | Recruiting | AUS | 0 |
NCT05091424 | Phase I | Mosunetuzumab-axgb + Tocilizumab | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05168904 | Phase Ib/II | CYC065 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | Recruiting | USA | 0 |
NCT05211336 | Phase I | Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | Recruiting | USA | 0 |
NCT05293912 | Phase I | SG2501 | SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. | Recruiting | USA | 0 |
NCT05317936 | Phase II | Pirtobrutinib + Venetoclax | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | Recruiting | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05405309 | Phase Ib/II | Olaparib + RP-3500 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) | Suspended | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | FRA | AUS | 3 |
NCT05458297 | Phase II | VLS-101 ARQ 531 + VLS-101 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 14 |
NCT05512390 | Phase I | ABBV-319 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
NCT05515406 | Phase I | ONO-7018 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | Recruiting | USA | 0 |
NCT05537766 | Phase II | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) | Recruiting | USA | ITA | FRA | ESP | DEU | 2 |
NCT05618028 | Phase I | ABBV-525 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | 1 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05873712 | Phase II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Recruiting | USA | AUS | 0 |
NCT05908409 | Phase Ib/II | IDP-121 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | ESP | 0 |
NCT05943496 | Phase I | Acalabrutinib + Obinutuzumab + Tafasitamab-cxix | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Phase I Study of Tazemetostat in Lymphoid Malignancies | Not yet recruiting | USA | 0 |
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Not yet recruiting | USA | 0 |